Combined therapy makes headway for liver cancer
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted...
2-May-2024 4:05 PM EDT
Add to Favorites